Physician profile
Mark E Lawlor
NPI 1326128547
$10,476.97
in general payments reported to CMS, 2019-2025
47 companies · $1,971 in 2025
The $1,971 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $1,319 · 2021: $1,431 · 2022: $1,752 · 2023: $1,834 · 2024: $1,367 · 2025: $1,971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,161 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,160.83 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,840.18 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,451.91 | 2021-2025 | |
| Novo Nordisk INC | $1,037.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $919.80 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $751.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $663.42 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $408.31 | 2021-2025 | |
| Amgen INC. | $357.56 | 2020-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.66 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $268.26 | 2019-2022 | |
| Allergan, INC. | $193.49 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $189.72 | 2019-2024 | |
| Esperion Therapeutics, INC. | $172.46 | 2022-2025 | Nexletol |
| Alphatec Spine, INC | $171.06 | 2025 | Invictus Mis |
| Janssen Pharmaceuticals, INC | $171.02 | 2019-2023 | Xarelto, Spravato |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lawlor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.